Thursday 7 May, 2026
Introduction and Objective: Pharmacological effects are driven by drug concentrations at the target site. However, direct measurement of tissue fluid…
Read moreAbstracts
PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION TO CHARACTERIZE PATIENTS WHO MAY BENEFIT FROM MONTHLY DOSING WITH AFLIBERCEPT 8 MG
Thursday 7 May, 2026
Introduction/Objectives: Aflibercept is a fully human recombinant fusion protein that acts as a soluble trap for vascular endothelial growth factor…
Read moreIMPACT OF CYP3A4 ONTOGENY ON PREDICTION OF DRUG CLEARANCE IN YOUNG PAEDIATRIC PATIENTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING
Thursday 7 May, 2026
Introduction: PBPK models account for developmental differences in physiology and pathology and thereby support precision dosing in paediatric populations. However,…
Read morePopulation pharmacokinetics supports pembrolizumab de-escalation while meeting target exposure in advanced non-small cell lung cancer
Thursday 7 May, 2026
Objectives: Immune checkpoint inhibitors (ICI) such as pembrolizumab have transformed outcomes in advanced non-small cell lung cancer (NSCLC) [1]. Still,…
Read moreUsage and regulatory acceptance of PBPK models in paediatric drug applications:a review of EMA and FDA public assessment reports
Thursday 7 May, 2026
Introduction: The recent decade has seen considerable growth of paediatric physiologically-based pharmacokinetic (PBPK) applications both in academia and industry, however,…
Read moreA Joint Model for Torque Teno Virus, Forced Expiratory Volume, Rejection, Infection and Death Dynamics Over a 6-Year Period After Lung Transplantation
Thursday 7 May, 2026
Background: Personalized tacrolimus therapy after transplantation mainly revolves around targeting trough concentrations (C0) in whole-blood to a range that minimizes…
Read moreAutomating Literature-Based Workflows with Delineate: From Evidence Synthesis to Model Reuse
Thursday 7 May, 2026
Objectives: Literature-based workflows are integral to drug development research, yet remain largely manual and resource-intensive. These workflows encompass a broad…
Read moreCAR-T PERSISTENCE MODELLING: BRIDGING BIOLOGY AND DATA
Thursday 7 May, 2026
Objectives CAR T cell kinetic models are increasingly enriched with biologically structural components that aim to represent processes such as…
Read moreAutomating Tumor Dynamics model discovery with Large Language Models
Thursday 7 May, 2026
BACKGROUND: Structural model selection for Tumor Dynamics (TD, or Tumor Growth Inhibition, TGI) is traditionally time-consuming and expert-driven, requiring iterative…
Read morePopulation Pharmacokinetics of Olokizumab in Healthy Volunteers and Rheumatoid Arthritis Subjects
Thursday 7 May, 2026
Objectives: Olokizumab (OKZ) is a humanized monoclonal antibody developed as an antagonist of interleukin-6 and used for the treatment of…
Read more